Canarypox and fowlpox viruses as recombinant vaccine vectors: A biological and immunological comparison

Antiviral Research

Volumn 88, Issue 1, 2010, Pages 53-63

  Zanotto, Carlo ^a   Pozzi, Eleana ^a   Pacchioni, Sole ^a   Volonté, Luca ^a   De Giuli Morghen, Carlo ^a   Radaelli, Antonia ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Canarypox virus; Cytokines; Fowlpox virus; Immune cells; Recombinant vaccines; VLP

Indexed keywords

GAG PROTEIN; POL PROTEIN; VIRUS VACCINE; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; CANARYPOX VIRUS; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENVELOPE GENE; FOWLPOX VIRUS; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MACROPHAGE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TRANSGENE; VERO CELL; VIRUS LIKE AGENT; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS REPLICATION; WILD TYPE;

AIDS VACCINES; ANIMALS; ANTIGENS, CD80; CANARYPOX VIRUS; CELL LINE; CYTOKINES; DENDRITIC CELLS; FLUORESCENT ANTIBODY TECHNIQUE; FOWLPOX VIRUS; GENE EXPRESSION; GENES, ENV; GENES, GAG; GENES, POL; GENETIC VECTORS; HIV-1; HUMANS; IMMUNIZATION; MACROPHAGES; MICROSCOPY, ELECTRON, TRANSMISSION; TRANSGENES; VACCINES, SYNTHETIC; VIRUS REPLICATION;

AVES; CANARYPOX VIRUS; FOWLPOX VIRUS; MAMMALIA;

EID: 77956930202     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.07.005     Document Type: Article

References (46)

1. Amara R.R., Villinger F., Staprans S.I., Altman J.D., Montefiori D., Kozyr N.L., Xu Y., Wyatt L.S., Earl P.L., Herndon J.G., McClure H.M., Moss B., Robinson H.L. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J. Virol. 2002, 76:7625-7631.
2. Baxby D., Paoletti E. Potential use of non-replicating vectors as recombinant vaccines. Vaccine 1992, 10:8-9.
3. Belshe R.B., Stevens C., Gorse G.J., Buchbinder S.P., Weinhold K., Sheppard H., Stablein D., Self S., McNamara J., Frey S., Flores J., Excler J.L., Klein M., Habib R.E., Duliege A.M., Harro C., Corey L., Keefer M., Mulligan M., Wright P., Celum C., Judson F., Mayer K., McKirnan D., Marmor M., Woody G. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J. Infect. Dis. 2001, 183:1343-1352.
4. Berencsi K., Gyulai Z., Gönczöl E., Pincus S., Cox W.I., Michelson S., Kari L., Meric C., Cadoz M., Zahradnik J., Starr S., Plotkin S. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J. Infect. Dis. 2001, 183:1171-1179.
5. Brown M., Zhang Y., Dermine S., de Wynter E.A., Hart C., Kitchener H., Stern P.L., Skinner M.A., Stacey S.N. Dendritic cells infected with recombinant fowlpox virus vectors are potent and long-acting stimulators of transgene-specific class I restricted T lymphocyte activity. Gene Ther. 2000, 7:1680-1689.
6. Cadoz M., Strady A., Meignier B., Taylor J., Tartaglia J., Paoletti E., Plotkin S. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 1992, 339:1429-1432.
7. Cao H., Kaleebu P., Hom D., Flores J., Agrawal D., Jones N., Serwanga J., Okello M., Walker C., Sheppard H., El-Habib R., Klein M., Mbidde E., Mugyenyi P., Walker B., Ellner J., Mugerwa R. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. J. Infect. Dis. 2003, 187:887-895.
8. Corey L., Mulligan M., Goepfert P., Sabbaj S., Clements-Mann M.L., Harrow C., et al. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with RGP120. J. Infect. Dis. 2001, 183:563-570.
9. Cottingham M.G., van Maurik A., Zago M., Newton A.T., Anderson R.J., Howard M.K., Schneider J., Skinner M.A. Different levels of immunogenicity of two strains of fowlpox virus as recombinant vaccine vectors eliciting T-cell responses in heterologous prime-boost vaccination strategies. Clin. Vaccine Immunol. 2006, 13:747-757.
10. de Bruyn G., Rossini A.J., Chiu Y.L., Holman D., Elizaga M.L., Frey S.E., Burke D., Evans T.G., Corey L., Keefer M.C. Safety profile of recombinant canarypox HIV vaccines. Vaccine 2004, 22:704-713.
11. De Rose R., Sullivan M.T., Dale C.J., Kelleher A.D., Emery S., Cooper D.A., Ramshaw I.A., Boyle D.B., Kent S.J. Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines: implications for future trials. Hum. Vaccines 2006, 2:134-136.
12. Earl P.L., Wyatt L.S., Montefiori D.C., Bilska M., Woodward R., Markham P.D., Malley J.D., Vogel T.U., Allen T.M., Watkins D.I., Miller N., Moss B. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric env protein boost in the SHIV rhesus macaque model. Virology 2002, 294:270-281.
13. Franchini G., Gurunathan S., Baglyos L., Plotkin S., Tartaglia J. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev. Vaccines 2004, 3:S75-S88.
14. Fries L.F., Tartaglia J., Taylor J., Kauffman E.K., Meignier B., Paoletti E., Plotkin S. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 1996, 14:428-434.
15. Goepfert P.A., Horton H., McElrath M.J., Gurunathan S., Ferrari G., Tomaras G.D., Montefiori D.C., Allen M., Chiu Y.L., Spearman P., Fuchs J.D., Koblin B.A., Blattner W.A., Frey S., Keefer M.C., Baden L.R., Corey L. High-dose recombinant canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J. Infect. Dis. 2005, 192:1249-1259.
16. Gupta K., Hudgens M., Corey L., McElrath M.J., Weinhold K., Montefiori D.C., Gorse G.J., Frey S.E., Keefer M.C., Evans T.G., Dolin R., Schwartz D.H., Harro C., Graham B., Spearman P.W., Mulligan M., Goepfert P. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J. Acquir. Immune Defic. Syndr. 2002, 29:254-261.
17. Hel Z., Nacsa J., Kelsall B., Tsai W.P., Letvin N., Parks R.W., Tryniszewska E., Picker L., Lewis M.G., Edghill-Smith Y., Moniuszko M., Pal R., Stevceva L., Altman J.D., Allen T.M., Watkins D., Torres J.V., Berzofsky J.A., Belyakov I.M., Strober W., Franchini G. Impairment of Gag-specific CD8+ T-cell function in mucosal and systemic compartments of simian immunodeficiency virus mac251- and simian-human immunodeficiency virus KU2-infected macaques. J. Virol. 2001, 75:11483-11495.
18. Irvine K.R., Chamberlain R.S., Shulman E.P., Rosenberg S.A., Restifo N.P. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J. Natl. Cancer Inst. 1997, 89:1595-1601.
19. Jin X., Ramanathan M., Barsoum S., Deschenes G.R., Ba L., Binley J., Schiller D., Bauer D.E., Chen D.C., Hurley A., Gebuhrer L., El Habib R., Caudrelier P., Klein M., Zhang L., Ho D.D., Markowitz M. Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J. Virol. 2002, 76:2206-2216.
20. Kelleher A.D., Puls R.L., Bebbington M., Boyle D.B., Ffrench R., Kent S.J., Kippax S., Purcell D.F., Thomson S., Wand H., Cooper D.A., Emery S. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 2006, 20:294-297.
21. Kim T.J., Tripathy D.N. Reticuloendotheliosis virus integration in the fowl poxvirus genome: not a recent event. Avian Dis. 2001, 45:663-669.
22. Kinloch-de Leos S., Hoen B., Smith D.E., Autran B., Lampe F.C., Philipps A.N., Goh L.E., Andersson J., Tsoukas C., Sonnerborg A., Tambussi G., Girard P.M., Bloch M., Battegay M., Carter N., El Habib R., Theofan G., Cooper D.A., Perrin L. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J. Infect. Dis. 2005, 192:607-617.
23. Kresge, K.J., 2009. Raft of results energizes researchers. IAVIReport () 13, pp. 4-17. http://www.iavireport.org/.
24. Nacsa J., Radaelli A., Edghill-Smith Y., Venzon D., Tsai W.P., De Giuli Morghen C., Panicali D., Tartaglia J., Franchini G. Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques. Vaccine 2004, 22:597-606.
25. Pacchioni S., Volonté L., Zanotto C., Pozzi E., De Giuli Morghen C., Radaelli A. Canarypox and fowlpox viruses as recombinant vaccine vectors: an ultrastructural comparative analysis. Arch. Virol. 2010, 155:915-924.
26. Pal R., Venzon D., Letvin N.L., Santra S., Montefiori D.C., Miller N.R., Tryniszewska E., Lewis M.G., VanCott T.C., Hirsch V., Woodward R., Gibson A., Grace M., Dobratz E., Markham P.D., Hel Z., Nacsa J., Klein M., Tartaglia J., Franchini G. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J. Virol. 2002, 76:292-302.
27. Picard O., Lebas J., Imbert J.C., Bigel P., Zagury D. Complication of intramuscular/subcutaneous immune therapy in severely immune-compromised individuals. J. Acquir. Immune Defic. Syndr. 1991, 4:641-643.
28. Puehler F., Schwarz H., Waidner B., Kalinowski J., Kaspers B., Bereswill S., Staeheli P. An interferon-gamma-binding protein of novel structure encoded by the fowlpox virus. J. Biol. Chem. 2003, 278:6905-6911.
29. Radaelli A., De Giuli Morghen C. Expression of HIV-1 envelope gene by recombinant avipoxvirus. Vaccine 1994, 12:1101-1109.
30. Radaelli A., Nacsa J., Tsai W.P., Edghill-Smith Y., Zanotto C., Elli V., Venzon D., Tryniszewska E., Markham P., Mazzara G.P., Panicali D., De Giuli Morghen C., Franchini G. Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251. Virology 2003, 312:181-195.
31. Rasband, W.S. ImageJ. (1.42q), 2009. , U.S. National Institutes of Health, Bethesda, Maryland, USA. http://rsb.info.nih.gov/ij/.
32. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., Benenson M., Gurunathan S., Tartaglia J., McNeil J.G., Francis D.P., Stablein D., Birx D.L., Chunsuttiwat S., Khamboonruang C., Thongcharoen P., Robb M.L., Michael N.L., Kunasol P., Kim J.H. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361:2209-2220.
33. Sabbaj S., Mulligan M.J., Hsieh R.-H., Belshe R.B., McGhee J.R. Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. AIDS 2000, 14:1365-1374.
34. Sadavis E.C., Chang P.W., Gulka G. Morphogenesis of canary poxvirus and its entrance into inclusion bodies. Am. J. Vet. Res. 1985, 46:529-535.
35. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 1994, 179:1109-1118.
36. Skinner M.A., Laidlaw S.M., Eldaghayes I., Kaiser P., Cottingham M.G. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Rev. Vaccines 2005, 4:63-76.
37. Somogyi P., Frazier J., Skinner M.A. Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells. Virology 1993, 197:439-444.
38. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 1991, 9:271-296.
39. Tartaglia J., Jarrett O., Neil J.C., Desmettre P., Paoletti E. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J. Virol. 1993, 67:2370-2375.
40. Taylor J., Paoletti E. Fowlpox virus as a vector in non-avian species. Vaccine 1988, 6:466-468.
41. Taylor J., Weinberg R., Kawaoka Y., Webster R.G., Paoletti E. Protective immunity against avian influenza induced by a fowlpox virus recombinant. Vaccine 1988, 6:504-508.
42. Taylor J., Weinberg R., Languet B., Desmettre P., Paoletti E. Recombinant fowlpox virus inducing protective immunity in nonavian species. Vaccine 1988, 6:497-503.
43. Taylor J., Trimarchi C., Weinberg R., Languet B., Guillemin F., Desmettre P., Paoletti E. Efficacy studies on a canarypox-rabies recombinant virus. Vaccine 1991, 9:190-193.
44. Taylor J., Weinberg R., Tartaglia J., Richardson C., Alkhatib G., Briedis D., Appel M., Norton E., Paoletti E. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology 1992, 187:321-328.
45. Tulman E.R., Alfonso C.L., Lu Z., Zsak L., Kutish G.F., Rock D.L. The genome of canarypox virus. J. Virol. 2004, 78:353-366.
46. Wild F., Giraudon P., Spehner D., Drillien R., Lecocq J.P. Fowlpox virus recombinant encoding the measles virus fusion protein: protection of mice against fatal measles encephalitis. Vaccine 1990, 8:441-442.